"Finding shell stocks with mergers in the works"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Deliberate dumping small shares on the ask to bring down the price = obvious
Guess you sold yours.
By the way paid promotions are usually very bad if the company itself is running the promo, but if it's a third party looking to make money on a pump, then it depends on the potential of the company. Remember, this did run up with no news which I think perhaps was a premature run-up...
Ask wall looks fake keeps changing to exact same amount as bid moves up and down, apparently trying to scare people into selling and putting off buyers in order to drive price down..we'll see....
Koos files for trademark
http://www.markhound.com/trademark/search/HEkxehnnR
Serial Number: 85664278
Filing Date: June 28th, 2012
Status/
Date: Review prior to publication completed.
October 31st, 2012
Live/Dead Indicator Live
Biological tissue, namely, blood, stem cells, umbilical cords and placentas for scientific and medical research use
This is the brand and trademark page for HEMXELLERATE which was created on June 28th, 2012 by REGEN BIOPHARMA INC., an Corporation located at Suite 304 in La Mesa, CALIFORNIA. REGEN BIOPHARMA INC. can be contacted at 619-702-1404, venturebridge@gmail.com or .
Review prior to publication completed.
Mark Type: Trademark
Standard Character: Yes
Register: Principal
Colors Claimed: None.
Disclaimer: No disclaimer.
Translation: No translation.
Consent: No consent required.
Owner Name: REGEN BIOPHARMA INC.
Address: Suite 304
City: La Mesa
State: CALIFORNIA
Zip Code: 91942
Country: UNITED STATES
Phone Number: 619-702-1404
Fax Number: 619-330-2328
Email Address: venturebridge@gmail.com
Correspondent Name: REGEN BIOPHARMA INC.
Firm Name: REGEN BIOPHARMA INC.
Address continued: 4700 SPRING ST STE 304
City: LA MESA
State: CALIFORNIA
Zip: 91942-0274
Country: UNITED STATES
Phone Number: 619-702-1404
Fax Number: 619-330-2328
Email Address: venturebridge@gmail.com
Signature Name/
Date: David R. Koos
June 28th, 2012
Position: Chairman and CEO
Phone Number: 619-702-1404
Class: 001
Status: Active
Description: Biological tissue, namely, blood, stem cells, umbilical cords and placentas for scientific and medical research use
Basis: 1(b)
First Use: December 31st, 1969
First use in Commerce: Not Available
Office Assigned: LAW OFFICE 113
Attorney Assigned: KERTGATE, AMY L
Current Location/
Date:: PUBLICATION AND ISSUE SECTION
October 31st, 2012
Date Status
October 26th, 2012 APPROVED FOR PUB - PRINCIPAL REGISTER
November 14th, 2012 NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
October 18th, 2012 ASSIGNED TO EXAMINER
July 10th, 2012 NOTICE OF PSEUDO MARK MAILED
July 7th, 2012 NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
July 2nd, 2012 NEW APPLICATION ENTERED IN TRAM
Guess you got nervous and dumped your shares.....
If it hits .0006 you don't want it...rather your buy should be no less than .0010 to keep the support at that level if it goes under...not a good sign.
mm's waiting for more 0.0012 to build on the ask then...BAM take it right out!
looks like the wall came down to 0.0013 nice! easier to take out at lower price!
I wonder if the wall by 0.0014 is gone by now for a finish up in the green......
funny that the ask is so small all day isn't it?!
Funny thing, so why are the mm's dragging it down?
If the bid size increases anymore people will start to hit the ask..
Bid keeps growing at 0.0012 going to force the mm's to buy higher!
put your order in at 0.0012 they keep putting shares there...
I think they really want it at 0.0011 !
Maybe, maybe not but my guess is it would cause a significant strain on them
mm's are putting a wall at 0.0014 so people will be scared into selling....if someone "by mistake" takes out that wall in one bite this will cause a giant run up with desperate mm's trying to get back in...
See their little ploy worked they just got it knocked back to 0.0012 with people selling
If it goes that low you don't want it, better to get in with a buy that pushes it upward better chance of staying up that way...
Agree, when 0.0014's go I think we are going to see the true beast of BMSN !
Here we go with hiding that ask again, these guys desperately want cheaper shares! Holding the ask just to keep it down and con people into selling...
Even better if that's the case...means the dilution was very justified and management really knows what their doing...
Although this does looks very interesting not $20 million rather much less see below sc 13G filing and this is only one of 3 filing and the other 2 are not Southridge Partners!!!!!!!!!!!
CUSIP No. 09065C106 13G Page 1 of 4
1. Name of Reporting Person Southridge Partners II LP
I.R.S. Identification No. of Above Person (entities only) 52-2090686
2. Check the Appropriate Box if a Member of a Group
(a) ¨
(b) x
3. SEC Use Only
4. Citizenship or Place of Organization Delaware
5. Sole Voting Power 46,212,122
Number of
Shares
Owned by 6. Shared Voting Power 46,212,122
Each
Reporting
Person
With 7. Sole Dispositive Power 46,212,122
8. Shared Dispositive Power 46,212,122
9. Aggregate Amount Beneficially Owned by Each Reporting Person 46,212,122
10. Check if the Aggregate Amount in Row 9 Excludes Certain Shares ¨
11. Percent of Class Represented by Amount in Row 9 9.999%
12. Type of Reporting Person PN
You still in on BMSN?
Based on the press release below and the 10-Q/A filed afterward, BMSN obviously didn't secure this funding. Either they never will or based on pre-determined milestones they will get it, in which case this will fly to 0.15
Or else maybe all this crazy volume is Southridge Partners buying on the open market and dragging it down to get in at a lower price?
Regen BioPharma Inc., Secures $20,000,000
Monday, 30 April 2012 14:00
SOURCE: Bio-Matrix Scientific Group Inc.
April 30, 2012 08:30 ET
Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 in Institutional Funding
Southridge Partners to Provide $20 Million in Funding for the Rapid Commercialization of Stem Cell Therapies
SAN DIEGO, CA--(Marketwire - Apr 30, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today it has formed a new subsidiary, Regen BioPharma, Inc. Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.
To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."
The Company also announced that it has secured $20,000,000 in financing from Southridge Partners II, LP of Ridgefield, Connecticut.
This agreement grants the Company the option to sell and obligates Southridge to purchase up to $20,000,000 of common stock over its term. The per share price will be determined based on market prices in accordance with an agreed upon formula and the Company is not obligated to draw on the facility.
The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Southridge of any shares issued to it under the agreement. Subject to the effectiveness of the registration statement and the satisfaction of other customary conditions, the Company may draw on the facility from time to time, as and when it determines appropriate, in accordance with the timing and volume provisions set forth in the agreement.
A spokesperson for the Company noted that Its investment banker, Christopher Schufeldt of Capital Path Securities was instrumental in arranging the funding agreement with Southridge Partners II LP.
About Bio-Matrix Scientific Group, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.
Areas of interest to the Company include:
Diabetes
Chronic Obstructive Pulmonary Disease (COPD)
Heart Related illness
Circulatory issues
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Last Updated ( Monday, 30 April 2012 14:04 )
this stock is pump and dump....
Silly, that's talking about dilution, not Koos's own shares!
Same way it got here from 0.0006 when dilution was over. Will continue on...
Don't make up stories, filings show he did no such thing...
With all that dilution, they sure have capital now!
Time to get in is Friday before it takes off...
What does that mean in English?
Does that increase the OS?
How much you gonna buy?!
How much do you have now?
I have about 10 million
mm's really have something up their sleeve,
25k sell after hours just to have the market open in red on Friday and try to scare some folks into selling!!!!!!!!!!!!!!!!!!!!!
Good for you! I loaded extra today as well have about 10 million
what does "follow them in" mean?
Looks like a huge buy filling AON......
mm's know this is going up their playing games for now.
Remember the rule, buy when others are fearful not greedy. Case in point BMSN !
Looks like another AON is filling up on the ask...so quiet....
Power up up up hour coming soon......
I repeat, REPEAT OF YESTERDAY!